Campora E, Vidali A, Mammoliti S, Ragni N, Conte P F
Dept. of Medical Oncology, National Institute for Cancer Research, Genoa.
Eur J Gynaecol Oncol. 1990;11(3):181-3.
Thirteen patients with recurrent or advanced endometrial carcinoma were treated with a combination of doxorubicin (40 mg/m2 IV) and cyclophosphamide (600 mg/m2 IV). All patients had been refractory to prior radiotherapy and hormone therapy. None of the patients had received prior chemotherapy. Six of the 13 patients (46%) achieved an objective response: 1 complete response (8%) and 5 partial responses (38%). Median overall survival was 10 months (range 3-20 months). Doxorubicin and cyclophosphamide is an active combination in patients with advanced endometrial cancer.
13例复发性或晚期子宫内膜癌患者接受了阿霉素（静脉注射40mg/m²）和环磷酰胺（静脉注射600mg/m²）联合治疗。所有患者对先前的放疗和激素治疗均无效。所有患者均未接受过先前的化疗。13例患者中有6例（46%）获得客观缓解：1例完全缓解（8%），5例部分缓解（38%）。总生存期中位数为10个月（范围3 - 20个月）。阿霉素和环磷酰胺联合治疗对晚期子宫内膜癌患者有效。
